Deal Watch: Momenta and Baxalta Pursuing Humira Biosimilar in U.S., E.U.

Biosimilar News  •  BPCIA and Related U.S. Statutes  •  Deal Watch

Momenta and Baxalta have announced a global clinical trial to study the safety, efficacy and immunogenicity of M923, a biosimilar to AbbVie’s Humira (adalimumab).  The trial is intended to support regulatory filings in both the U.S. and the E.U. with the goal of launching commercially in 2018.

Read more here.

Download PDF

Comments are closed.